Cart
Account
Your Orders
Sign In
CRISPR in Cancer Therapeutics: CAR-T, NK, TCR and Beyond
Contents
Undergoing cancer therapy can be a harrowing experience for many, especially for patients with advanced, metastatic types of cancer with limited options for therapy and limited time. Access to personalized genomic information and tailored therapies not only extend the survival times but also help maintain the quality of life with fewer side effects.
Synthego sat down with Bryce Olson, Global Marketing Director at Intel Corporation, who is actively battling advanced-stage prostate cancer. In the current blog post, we will learn all about Bryce’s experiences with his cancer therapy, the ups and downs during his journey, how he pioneered the “Sequence Me” movement, and the future potential of genome engineering technologies for cancer treatment and hopefully cancer cure. Here are some of the significant highlights from the discussion.
5 Key Takeaways from this Podcast on Personalized Approaches to Advanced Cancer Treatment
1. Standard Care for Advanced Metastatic CancerThe standard approach to cancer treatment is “one size fits all,” which is sadly true for highly advanced metastatic cancer patients. Patients with aggressive prostate cancer are often offered the same care as those with a milder, more indolent form of the disease, and the best they can do is hope to respond to the treatment.
Time in Podcast: 2:08
The standard approach to cancer treatment is “one size fits all,” which is sadly true for highly advanced metastatic cancer patients. Patients with aggressive prostate cancer are often offered the same care as those with a milder, more indolent form of the disease, and the best they can do is hope to respond to the treatment.
Time in Podcast: 2:08
2. Building Insights with Personalized Genomics and Success with Clinical TrialBryce demanded a personalized genomic sequencing of his tumors, overruling his oncologist, which led to some exciting breakthroughs in his treatment. The sequencing results revealed specific mutations that were driving his tumor growth. Braced with this unique molecular information, Bryce was able to find a clinical trial that was a perfect fit for his type of cancer.
Time in Podcast: 4:16
Bryce demanded a personalized genomic sequencing of his tumors, overruling his oncologist, which led to some exciting breakthroughs in his treatment. The sequencing results revealed specific mutations that were driving his tumor growth. Braced with this unique molecular information, Bryce was able to find a clinical trial that was a perfect fit for his type of cancer.
Time in Podcast: 4:16
3. The "Sequence Me" Movement and Possibilities with Precision MedicineHis initial success and remission with the personalized genomic sequencing led Bryce to initiate the “Sequence Me” movement. It was a phenomenal success and helped create the much-needed awareness among cancer patients to seek genomic sequencing information as an integral part of their therapy.
Time in Podcast: 8:15
His initial success and remission with the personalized genomic sequencing led Bryce to initiate the “Sequence Me” movement. It was a phenomenal success and helped create the much-needed awareness among cancer patients to seek genomic sequencing information as an integral part of their therapy.
Time in Podcast: 8:15
4. Cell and Gene Therapy for Advanced-Stage Cancer PatientsIt is fairly common for aggressive cancers to accumulate mutations as they progress and develop resistance to therapy. Bryce’s cancer is at a stage where he has progressed despite several lines of treatment and is almost running out of options. Cell-based immunotherapies are the best bet for him and for patients in similar stages of progression. Bryce describes his cautious optimism with potential CAR-T Cell Therapy.
Time in Podcast: 20:11
It is fairly common for aggressive cancers to accumulate mutations as they progress and develop resistance to therapy. Bryce’s cancer is at a stage where he has progressed despite several lines of treatment and is almost running out of options. Cell-based immunotherapies are the best bet for him and for patients in similar stages of progression. Bryce describes his cautious optimism with potential CAR-T Cell Therapy.
Time in Podcast: 20:11
5. Cancer Patients are Waiting: Next Steps Towards "Engineer Me"Bryce is cautiously optimistic about the chances of success with cell-based immunotherapies in his own case and talks about current challenges with solid tumor treatments, as well as short- and long-term changes required to address them.
Time in Podcast: 27:55
Bryce is cautiously optimistic about the chances of success with cell-based immunotherapies in his own case and talks about current challenges with solid tumor treatments, as well as short- and long-term changes required to address them.
Time in Podcast: 27:55
Background and Diagnosis: The Grim Beginnings
In the following sections, we will learn more about Bryce’s background and how he came to terms with his diagnosis. Learn how he embarked on this path of discovery around his own condition.
Minu: Could you please tell us a little bit about yourself?
Minu: Could you please tell us a little bit about yourself?Bryce: Thanks for having me on. I am initially a guy from the tech industry, who at 44 years old got diagnosed with super aggressive metastatic prostate cancer and knew nothing about cancer. I didn't pay attention to biology and didn't like science in high school. I didn't really focus on the space at all.
When somebody like that gets diagnosed with cancer, you find yourself in a paternalistic relationship with your doctor. You're going to do whatever the doctor says. I found myself all of a sudden thrust into this standard of care, “one size fits all” treatment paradigm where even with my cancer being more aggressive than the average patient, I'm still going to get the same trial-and-error care as everybody else. This “spin the wheel” of cut, burn, poison, and in my case of prostate cancer, try to starve cancer from hormones and testosterone, seemed really just wrong. So, sure enough, I went through all those treatments and they worked for a little while, but it wasn't too long before I started to build up a resistance, saw my cancer come back, and I really started to lose hope.
Bryce: Thanks for having me on. I am initially a guy from the tech industry, who at 44 years old got diagnosed with super aggressive metastatic prostate cancer and knew nothing about cancer. I didn't pay attention to biology and didn't like science in high school. I didn't really focus on the space at all.
When somebody like that gets diagnosed with cancer, you find yourself in a paternalistic relationship with your doctor. You're going to do whatever the doctor says. I found myself all of a sudden thrust into this standard of care, “one size fits all” treatment paradigm where even with my cancer being more aggressive than the average patient, I'm still going to get the same trial-and-error care as everybody else. This “spin the wheel” of cut, burn, poison, and in my case of prostate cancer, try to starve cancer from hormones and testosterone, seemed really just wrong. So, sure enough, I went through all those treatments and they worked for a little while, but it wasn't too long before I started to build up a resistance, saw my cancer come back, and I really started to lose hope.
"I didn't think I'd see my daughter get out of elementary school. It was around this time when Duke Health did this study and it basically showed that if you were a guy who had metastatic prostate cancer that had spread to the bones and if you had progressed off of chemo, you had about 21 months to live. So I started getting really depressed, kind of came to terms with my own mortality, but I wanted my last days to matter."
Bryce Olson
First Shot at a Silver Lining: Initial Insights from Genomic Sequencing
Bryce goes on to describe how he first learned about genomic sequencing and how genomic data could provide meaningful insights into individual cancer progression.
Bryce: I worked for this large tech company, Intel Corporation. They had a group that was focused on the health and life sciences sector and was helping large hospitals, pharmaceutical companies, and cancer researchers make new discoveries and just process, store and analyze data in new ways. I didn't really know much about what they were doing, but I wanted to use my experience and background to get into that group.
When I got in, it blew my mind because I learned about genomics and how we were helping the largest cancer centers and genomic research centers like Beijing Genomic Institute and the Broad Institute find new insights with a massive amount of genomic data.
I got upset at that point because nobody was doing this for me. I wasn't getting any of this personalized for me. So I demanded it from my doctor and they weren't really supportive at first. They were just telling me, "Look, we can do this for you. We can sequence your cancer, but it's not really going to change what we're going to offer you. We're going to give you the same standard of care treatments that we have slotted for everybody." And at that point, I was like, "I don't care. Let's just do this because it could potentially give us some new insight."
It’s a Perfect Match: Early Success in a Clinical Trial
When the results came in, it was great news for Bryce. He not only had a better understanding of molecular features unique to his cancer, but he was also able to match with a clinical trial that was enrolling patients for a drug that perfectly targeted his cancer.
Bryce: I found out from the pathologist that I had a mutation in the PI3K kinase signaling pathway, and it was hyperactive because of the mutation and a tumor suppressor gene called PTEN. If I could find an early drug that would inhibit cancer on that pathway, I could hope for some new success.
So I sat down with the oncologist and we found a Phase I clinical trial at Cedar Sinai in LA. I called them up and told them that I wanted to enroll in the trial, and had genomic sequencing data. They were surprised, "You have what?"
"I said, "I've got genomic sequencing data. I know I'm a perfect molecular match to the drug you're trying to test. The drug you're testing is inhibiting the way that my cancer uniquely grows. "
Bryce Olson
I became eligible, enrolled in the trial, and shut cancer down for two years between 2015 and 2017 with that strategy. If you flash forward to today, I'm eight years dealing with aggressive metastatic disease in the bone. I've been on 11 lines of therapy, including four different clinical trials at four different academic cancer centers, and that includes a few off-label drugs and I've more than tripled my median survival. I think I'm doing pretty well with the strategy.
Beginning of the “Sequence Me” Movement and Success
Kevin: Could you tell us about the "Sequence Me" Movement that you started?Bryce: I was motivated by the success that I had. I felt morally obligated to figure out a way to get the word. I wanted to come up with something actionable, that would make sense, something simple and effective. I just thought of “Sequence Me”, like let's do this, let's just sequence me! Go into your doctor’s office and demand it. So, I started creating a multimedia approach with this.
We created some videos highlighting my story and what we're trying to do with the “Sequence Me” movement is driving people to demand sequencing for their disease and open up new doors. I was fortunate enough to get some interest from big press and fortunate enough to get on stage and talk about this at very large healthcare information management meetings and a ton of other places. It was great coming off a stage and seeing how this message resonated with so many people, I would get bombarded with people that wanted to talk more about it with me.
So, I created a website called sequenceme.org. This is the first website, I believe, with a chatbot that speaks genomics. There are a lot of Q&As and FAQs available for patients. We have a battle card that they can download and bring to the doctor's appointment because sometimes doctors are still not very forthright about making these technologies available to patients.
The message resonates with a lot of people; I know there's been thousands and thousands of people that have bought these t-shirts that say “Sequence Me” on them and they've worn them into their doctor's offices and have demanded their tumors to be sequenced. We're not at the place where every cancer patient gets sequenced today, but it's a lot better now in 2022. If you have advanced cancer and you go into your doctor's office, chances are pretty high that you're going to get some level of profiling, and hopefully, this movement has helped a little bit with that.
It's critical to open up new doors beyond the small amount of standard of care drugs. Without understanding what's driving your disease, you're not getting access to off-label drugs that are approved for somebody else's cancer, but that could be a good thing for you and for clinical trials. Only 4% of cancer patients actually go on to clinical trials, 96% of them never even go onto it, and that’s where all the new stuff is!
Bryce: I was motivated by the success that I had. I felt morally obligated to figure out a way to get the word. I wanted to come up with something actionable, that would make sense, something simple and effective. I just thought of “Sequence Me”, like let's do this, let's just sequence me! Go into your doctor’s office and demand it. So, I started creating a multimedia approach with this.
We created some videos highlighting my story and what we're trying to do with the “Sequence Me” movement is driving people to demand sequencing for their disease and open up new doors. I was fortunate enough to get some interest from big press and fortunate enough to get on stage and talk about this at very large healthcare information management meetings and a ton of other places. It was great coming off a stage and seeing how this message resonated with so many people, I would get bombarded with people that wanted to talk more about it with me.
So, I created a website called sequenceme.org. This is the first website, I believe, with a chatbot that speaks genomics. There are a lot of Q&As and FAQs available for patients. We have a battle card that they can download and bring to the doctor's appointment because sometimes doctors are still not very forthright about making these technologies available to patients.
The message resonates with a lot of people; I know there's been thousands and thousands of people that have bought these t-shirts that say “Sequence Me” on them and they've worn them into their doctor's offices and have demanded their tumors to be sequenced. We're not at the place where every cancer patient gets sequenced today, but it's a lot better now in 2022. If you have advanced cancer and you go into your doctor's office, chances are pretty high that you're going to get some level of profiling, and hopefully, this movement has helped a little bit with that.
It's critical to open up new doors beyond the small amount of standard of care drugs. Without understanding what's driving your disease, you're not getting access to off-label drugs that are approved for somebody else's cancer, but that could be a good thing for you and for clinical trials. Only 4% of cancer patients actually go on to clinical trials, 96% of them never even go onto it, and that’s where all the new stuff is!
What does the Future Hold For Cell and Gene Therapies in Cancer?
Cancers evolve with standard treatment and as time progresses it is natural for tumors to acquire mutations and subsequently develop resistance. In this section, we’ll hear Bryce explain how he has progressed despite multiple lines of therapy, including off-label, targeted drugs. As he is running out of options, he’s looking ahead to cell-based therapies that rely on genome engineering technologies such as CRISPR genome editing.
Minu: What do you think of cell and gene therapies for cancer, are they something that can help you? Are you actively involved in any such trials?Bryce: Yeah, I'm glad you brought that up. Here's where, and it kind of connects to some of the shortcomings that somebody like me is starting to experience with just genomics alone. As I mentioned that when I first got sequenced and I found out that I had an altered PI3K signaling pathway, that was a great target for me. The challenge, though, is that cancer will ultimately mutate and morph around that type of blockade in different ways such that it can become resistant.
I can see this with longitudinal genomics that I've done year after year after year, I've acquired new alterations over time because of all the drugs that I've been on. So now I'm looking at cellular immunotherapies and cell and gene therapies. These have been amazing for blood cancers, but they're still a little bit disappointing for solid tumors.
I'm cautiously optimistic. I want to get on one such trial. It's probably going to be the path that I go on next. Matter of fact, I am in the process of becoming eligible for a CAR-T cell therapy trial that's called a PSCA, prostate stem cell antigen CAR-T. It's out of the City of Hope. If I am eligible, we go through the long process of getting autologous CAR-T cells built for me, which involves harvesting my T cells, editing and expanding them, and then putting them back into me, which is a two to three-month process. Meanwhile, my cancer doesn't stop growing.
I'm optimistic because significant objective responses are happening. But again, I'm concerned that there are certain things that are going to make it possibly not work, and that I think CRISPR could actually really fix those. So I'm excited about where the future's going.
Bryce: Yeah, I'm glad you brought that up. Here's where, and it kind of connects to some of the shortcomings that somebody like me is starting to experience with just genomics alone. As I mentioned that when I first got sequenced and I found out that I had an altered PI3K signaling pathway, that was a great target for me. The challenge, though, is that cancer will ultimately mutate and morph around that type of blockade in different ways such that it can become resistant.
I can see this with longitudinal genomics that I've done year after year after year, I've acquired new alterations over time because of all the drugs that I've been on. So now I'm looking at cellular immunotherapies and cell and gene therapies. These have been amazing for blood cancers, but they're still a little bit disappointing for solid tumors.
I'm cautiously optimistic. I want to get on one such trial. It's probably going to be the path that I go on next. Matter of fact, I am in the process of becoming eligible for a CAR-T cell therapy trial that's called a PSCA, prostate stem cell antigen CAR-T. It's out of the City of Hope. If I am eligible, we go through the long process of getting autologous CAR-T cells built for me, which involves harvesting my T cells, editing and expanding them, and then putting them back into me, which is a two to three-month process. Meanwhile, my cancer doesn't stop growing.
I'm optimistic because significant objective responses are happening. But again, I'm concerned that there are certain things that are going to make it possibly not work, and that I think CRISPR could actually really fix those. So I'm excited about where the future's going.
CRISPR in Cancer Therapeutics: CAR-T, NK, TCR and Beyond
Challenges with Cell-based Immunotherapy in Solid TumorsMinu: What are some of the things that could be changed to make these therapies work in solid tumors?
Bryce: Yeah, that's a great question! So I think maybe this is long-term to medium-term, but there are a few things that are challenging today with CAR T-cells. The reason why they work really well with blood cancers is that they're circulated in the bloodstream and in the lymphatic system so there's tons of interaction with blood cancers. But in a solid tumor, it actually needs to penetrate the tumor tissue.
The other challenge with solid tumors is that you need an antigen target. There's a lot of heterogeneity if you will, in the antigen expression. So even if you go after one, you may not really stop it because there are all these other antigens that they're using to grow.
Then I think the biggest challenge is the immunosuppressive tumor microenvironment. The way I like to think about this is if cancer is the castle, then the moat that's surrounding the castle that provides a line of defense, that's the tumor microenvironment.
Minu: What are some of the things that could be changed to make these therapies work in solid tumors?
Bryce: Yeah, that's a great question! So I think maybe this is long-term to medium-term, but there are a few things that are challenging today with CAR T-cells. The reason why they work really well with blood cancers is that they're circulated in the bloodstream and in the lymphatic system so there's tons of interaction with blood cancers. But in a solid tumor, it actually needs to penetrate the tumor tissue.
The other challenge with solid tumors is that you need an antigen target. There's a lot of heterogeneity if you will, in the antigen expression. So even if you go after one, you may not really stop it because there are all these other antigens that they're using to grow.
Then I think the biggest challenge is the immunosuppressive tumor microenvironment. The way I like to think about this is if cancer is the castle, then the moat that's surrounding the castle that provides a line of defense, that's the tumor microenvironment.
Optimism for the Future of Immuno OncologyAs he forges with optimism, while being fully aware of all challenges that lie ahead on his path, Bryce also talks about the next steps in approaching cancer treatment. He talks about expanding diagnostic options for immune profiling solid tumors and building awareness around cell and gene therapies.
As he forges with optimism, while being fully aware of all challenges that lie ahead on his path, Bryce also talks about the next steps in approaching cancer treatment. He talks about expanding diagnostic options for immune profiling solid tumors and building awareness around cell and gene therapies.
Kevin: What are the next steps of the " Sequence Me" movement? Are you now focusing on how to educate patients on what therapies are available to them?Bryce: Yeah, I'm glad you asked about that. Because what I would love to do is at some point, add a new chapter to Sequence Me and maybe call it “Engineer Me”! However, I personally need to have some success with cellular immunotherapy or cell and gene therapy before I can go out and talk about it. Hopefully, in the next two or three months, I'm going to go do this CAR-T therapy at the City of Hope. If I'm a responder, then that's going to give me a lot more confidence to kind of go out and start to build awareness for this.
Bryce: Yeah, I'm glad you asked about that. Because what I would love to do is at some point, add a new chapter to Sequence Me and maybe call it “Engineer Me”! However, I personally need to have some success with cellular immunotherapy or cell and gene therapy before I can go out and talk about it. Hopefully, in the next two or three months, I'm going to go do this CAR-T therapy at the City of Hope. If I'm a responder, then that's going to give me a lot more confidence to kind of go out and start to build awareness for this.
Future Diagnostics for Cancer Immune ProfilingBryce: One of the big challenges that exist is from an actionability perspective, if you think about it, a cancer patient can't demand cellular immunotherapy profiling today. There's no diagnostic that exists today. There should be, but there isn't.
Once we get to a point where there are a few diagnostic companies that are able to help profile what would be good cellular immunotherapy based on that individual immune function, then I would love to shine a light on those companies because then patients could go get diagnosed. We're not quite there yet, we just need to get a little bit further along.
Bryce: One of the big challenges that exist is from an actionability perspective, if you think about it, a cancer patient can't demand cellular immunotherapy profiling today. There's no diagnostic that exists today. There should be, but there isn't.
Once we get to a point where there are a few diagnostic companies that are able to help profile what would be good cellular immunotherapy based on that individual immune function, then I would love to shine a light on those companies because then patients could go get diagnosed. We're not quite there yet, we just need to get a little bit further along.
CRISPR CAR-T cells: Edited T Cells Are Revolutionizing Cancer Treatment
CAR-T cell therapy is a form of immunotherapy used to treat cancer. CRISPR-Cas9 gene editing has recently been used to increase the safety and efficacy of CAR-T therapies. This article explores CAR-T therapy, how CRISPR can be used to improve CAR-T, and how CRISPR-edited CAR-T cells are revolutionizing cancer treatment.
The Role of CRISPR and Genome Editing Technologies in Cell-based Therapies
Bryce: I think CRISPR is going to add some really amazing innovation, to these cellular immunotherapies and CAR-Ts. For example, I feel like my T cells today might just be moving really slowly, I've been on so many different treatments over the last eight years that the health of my T cells may not be that great. So when I go and get an autologous CAR-T therapy that's using my own T cells, I worry about whether are they going to be effective enough.
"When you use CRISPR though, you could get a lot more precision. For example, when you insert the CAR into the genome of the T cells so that you get really good expression levels, that would be cool! You could use CRISPR to correct genetic defects on these autologous T-cells. "
Bryce Olson
Bryce: So they could just be more efficient killers and then I think one of the big challenges with autologous CAR T-cells is that it just takes very long to get them ready for a patient. You’ve got to harvest the T cells, edit them, expand them, then transfusing them back into the patient. It's very time-consuming. It was very expensive.
"Imagine using CRISPR to just create off-the-shelf universal CAR-Ts, allogeneic CAR-Ts, so you don't have to do all that harvesting and editing and expanding. You just find a donor and use CRISPR to knock out the genes that cause an immune rejection, so you don't have graft versus host problems. When we get there, pharmaceutical companies can generate these CAR-Ts so much faster. "
Bryce Olson
Final Words and Synthego’s Vision to Help Accelerate Cell and Gene Therapies
In the final section, Bryce continues to explore how genome editing technologies can work wonders in the field of cell and gene therapies, especially for advanced-stage cancer patients.
Minu: I would like to thank you for taking the time and talking to us!Bryce: Sure! I want every advanced cancer patient to understand what's driving their disease. But, I also do want to see the cellular immunotherapy space evolve so we can get the right kind of diagnostics and then help move us into the right type of therapies.
As we get closer to seeing drugs get FDA approved for solid tumors, pharmaceutical companies are going to want to shine a light on them then, but even right now, they need to recruit patients.
I've talked to CEOs of a number of phase one clinical trials, and small biotech companies that are creating these CARs. They want patients to inquire about them because they got to recruit patients, and it's tough to recruit patients.
Kevin: Bryce, I also want to extend my gratitude to you as well. I hope that through this podcast episode, more people will learn about the “Sequence Me” movement that you've started for both patients and biotech companies.
We know this because, at Synthego, our mission really is to accelerate the movement of genome engineering technology from research into the clinic. That's really why we were founded. We wanted to make genome engineering technologies and engineered cell-based therapies really accessible to everyone that needs them. So, we are here supporting cell and gene therapy companies in these efforts in their clinical research and clinical trials.
At Synthego, we're ready and we're already helping some companies move faster, and we want to keep moving forward in that direction. And it's so inspiring to hear your story and just thank you for your time and for everything that you're doing both to be an advocate for your own health, as well as to help others that are in desperate need of these next-generation treatments.
Bryce: Thank you very much!
Bryce: Sure! I want every advanced cancer patient to understand what's driving their disease. But, I also do want to see the cellular immunotherapy space evolve so we can get the right kind of diagnostics and then help move us into the right type of therapies.
As we get closer to seeing drugs get FDA approved for solid tumors, pharmaceutical companies are going to want to shine a light on them then, but even right now, they need to recruit patients.
I've talked to CEOs of a number of phase one clinical trials, and small biotech companies that are creating these CARs. They want patients to inquire about them because they got to recruit patients, and it's tough to recruit patients.
Kevin: Bryce, I also want to extend my gratitude to you as well. I hope that through this podcast episode, more people will learn about the “Sequence Me” movement that you've started for both patients and biotech companies.
We know this because, at Synthego, our mission really is to accelerate the movement of genome engineering technology from research into the clinic. That's really why we were founded. We wanted to make genome engineering technologies and engineered cell-based therapies really accessible to everyone that needs them. So, we are here supporting cell and gene therapy companies in these efforts in their clinical research and clinical trials.
At Synthego, we're ready and we're already helping some companies move faster, and we want to keep moving forward in that direction. And it's so inspiring to hear your story and just thank you for your time and for everything that you're doing both to be an advocate for your own health, as well as to help others that are in desperate need of these next-generation treatments.
Bryce: Thank you very much!
CRISPR Cell and Gene Therapies: Key Challenges in Clinical Development
Researchers face many hurdles when developing CRISPR therapy products, including the procurement of true GMP reagents, unclear regulatory guidelines, lack of consistency during development, and shortages of qualified experts. Read more about these issues in CRISPR therapy development and strategies to overcome them.
Other CRISPR and Gene Therapy Podcasts You May Enjoy
If you’re looking for new podcasts about genome engineering and personalized medicine, and enjoyed listening to this podcast, here’s a list that you may be interested in:
Andre Watson Develops Delivery Platforms To Make Gene Therapy a Reality
Andre Watson, CEO and co-founder of Ligandal, tell us how his company is developing a delivery platform to make gene therapy a reality for the public.
In this episode we chat with Andre Watson, CEO, and co-founder of Ligandal, a company working to make gene therapy real. They focus on improving the payload delivery of these therapies - something that hasn’t been a real focus of developing CRISPR applications and creates a bottleneck for many amazing new technologies.
The Promising Potential of CRISPR Editing in Stem Cells: A Chat with Bill Skarnes
CRISPR has simplified gene editing in stem cells, thus showing promising potential in therapy development. In this podcast episode, Dr. Bill Skarnes from the Jackson Laboratory elaborates on how CRISPR-edited stem cells are transforming disease modeling studies.
CRISPR has simplified gene editing in stem cells, thus showing promising potential in therapy development. In this podcast episode, Dr. Bill Skarnes from the Jackson Laboratory elaborates on how CRISPR-edited stem cells are transforming disease modeling studies
Sherlock Founders Crack the Case of CRISPR Diagnostics
CRISPR is going beyond gene editing into a new area: diagnostics. Omar Abudayyeh and Jonathan Gootenberg, co-founders of SHERLOCK Biosciences, talk about the present advances and future of CRISPR diagnostics.
CRISPR is going beyond gene editing into a new area: diagnostics. Omar Abudayyeh and Jonathan Gootenberg, co-founders of SHERLOCK Biosciences, talk about the present advances and future of CRISPR diagnostics.
Dr. Avery Posey, Jr. is leading the charge on CAR T cell therapy research and working towards bringing this technology to cancer patients as soon as possible. In this episode, he explains how CAR T works, what stage it’s in now, and how it will help revolutionize the treatment of cancer.
